Abstract Title:

Phosphate binders in CKD: chalking out the differences.

Abstract Source:

Pediatr Nephrol. 2010 Mar;25(3):385-94. Epub 2009 Nov 7. PMID: 19898877

Abstract Author(s):

Lesley Rees, Rukshana C Shroff

Article Affiliation:

Department of Nephrology, Great Ormond Street Hospital for Children NHS Trust, London, UK. [email protected]

Abstract:

Plasma phosphate levels are important in the evolution of hyperparathyroidism and ectopic calcification in chronic kidney disease (CKD). Although dietary management may be adequate to control plasma phosphate in its early stages, most patients develop hyperphosphataemia by CKD stages 3-4 and require the addition of a phosphate binder. Calcium-containing phosphate binders are the most used and cheapest binders but have fallen out of favour because of the potential for positive calcium balance and calcium toxicity. This problem may be attenuated by newer phosphate binders such as sevelamer hydrochloride and lanthanum carbonate. In this review, the role of phosphate as a uraemic toxin and the advantages and disadvantages of the currently available phosphate binders are discussed.

Study Type : Commentary
Additional Links

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.